Cited by 620AI in cancer detectionArtificial Intelligence in Healthcare and EducationProstate Cancer Diagnosis and Treatment

Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study

Open access
Ström, Peter, Kartasalo, Kimmo, Olsson, Henrik, Solorzano, Leslie, Delahunt, Brett, Berney, Daniel M, Bostwick, David G, Evans, Andrew J +24 more·2020·The Lancet Oncology

Abstract

Background An increasing volume of prostate biopsies and a worldwide shortage of urological pathologists puts a strain on pathology departments. Additionally, the high intra-observer and inter-observer variability in grading can result in overtreatment and undertreatment of prostate cancer. To alleviate these problems, we aimed to develop an artificial intelligence (AI) system with clinically acceptable accuracy for prostate cancer detection, localisation, and Gleason grading.Methods We digitised 6682 slides from needle core biopsies from 976 randomly selected participants aged 50-69 in the Swedish prospective and population-based STHLM3 diagnostic study done between May 28, 2012, and Dec 30, 2014 (ISRCTN84445406), and another 271 from 93 men from outside the study. The resulting images were used to train deep neural networks for assessment of prostate biopsies. The networks were evaluated by predicting the presence, extent, and Gleason grade of malignant tissue for an independent test dataset comprising 1631 biopsies from 246 men from STHLM3 and an external validation dataset of 330 biopsies from 73 men. We also evaluated grading performance on 87 biopsies individually graded by 23 experienced urological pathologists from the International Society of Urological Pathology. We assessed discriminatory performance by receiver operating characteristics and tumour extent predictions by correlating predicted cancer length against measurements by the reporting pathologist. We quantified the concordance between grades assigned by the AI system and the expert urological pathologists using Cohen's kappa.Findings The AI achieved an area under the receiver operating characteristics curve of 0·997 (95% CI 0·994-0·999) for distinguishing between benign (n=910) and malignant (n=721) biopsy cores on the independent test dataset and 0·986 (0·972-0·996) on the external validation dataset (benign n=108, malignant n=222). The correlation between cancer length predicted by the AI and assigned by the reporting pathologist was 0·96 (95% CI 0·95-0·97) for the independent test dataset and 0·87 (0·84-0·90) for the external validation dataset. For assigning Gleason grades, the AI achieved a mean pairwise kappa of 0·62, which was within the range of the corresponding values for the expert pathologists (0·60-0·73).Interpretation An AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking comparable to that of international experts in prostate pathology. Clinical application could reduce pathology workload by reducing the assessment of benign biopsies and by automating the task of measuring cancer length in positive biopsy cores. An AI system with expert-level grading performance might contribute a second opinion, aid in standardising grading, and provide pathology expertise in parts of the world where it does not exist.Funding Swedish Research Council, Swedish Cancer Society, Swedish eScience Research Center, EIT Health.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30738-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ström, P., Kartasalo, K., Olsson, H., Solorzano, L., Delahunt, B., Berney, D. M., Bostwick, D. G., Evans, A. J., Grignon, D. J., Humphrey, P. A., Iczkowski, K. A., Kench, J. G., Kristiansen, G., van der Kwast, T. H., Leite, K. R. M., McKenney, J. K., Oxley, J., Pan, C.-C., Samaratunga, H., Srigley, J. R., Takahashi, H., Tsuzuki, T., Varma, M., Zhou, M., Lindberg, J., Lindskog, C., Ruusuvuori, P., Wählby, C., Grönberg, H., Rantalainen, M., Egevad, L., & Eklund, M.
Affiliations
  • Karolinska Institutet (SE)
  • Tampere University (FI)
  • Uppsala University (SE)
  • University of Otago (NZ)
  • Queen Mary University of London (GB)
  • Bostwick Laboratories (US)
  • University Health Network (CA)
  • Indiana University School of Medicine (US)
  • Yale University (US)
  • Medical College of Wisconsin (US)
  • The University of Sydney (AU)
  • University Hospital Bonn (DE)
  • Cleveland Clinic (US)
  • Southmead Hospital (GB)
  • Taipei Veterans General Hospital (TW)
  • The University of Queensland (AU)
  • University of Toronto (CA)
  • Jikei University School of Medicine (JP)
  • Aichi Medical University (JP)
  • University Hospital of Wales (GB)
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
Eklund, Martin
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-02
Volume
21
Issue
2
Pages
222-232
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2999399991
Cited by
620
References
31
Citations by year
2026: 60 · 2025: 95 · 2024: 102 · 2023: 103 · 2022: 111 · 2021: 98 · 2020: 51
FWCI
35.68
Type
journal article
Language
en
Update notices
erratum (2020-02-01)
Open access
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
  • Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by-nc-nd)
Funders
  • Tampereen Yliopisto
  • European Research Council (ERC-2015-CoG 682810)
  • Walter Ahlströmin Säätiö
  • Emil Aaltosen Säätiö
  • Academy of Finland (313921)
  • Tekniikan Edistämissäätiö
  • Cancerfonden
  • Syöpäjärjestöt
  • Vetenskapsrådet
  • Forskningsrådet om Hälsa, Arbetsliv och Välfärd
  • Tampereen Teknillinen Yliopisto
  • EIT Health
  • Orionin Tutkimussäätiö
  • KAUTE-Säätiö
Topics
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
Keywords
prostate cancer, artificial intelligence, Gleason grading, core needle biopsy, deep neural network, computer-aided diagnosis, tumor localization, observer variability, external validation, overtreatment and undertreatment, prostate cancer screening, histopathology image analysis
MeSH terms
Aged, Artificial Intelligence, Biopsy, Diagnosis, Computer-Assisted, Humans, Image Interpretation, Computer-Assisted, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Prostatic Neoplasms, Sweden, Reproducibility of Results, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review